Hans Clevers, MD, PhD, will describe his groundbreaking research in the development of organoid technology and how it can be applied to liver and biliary disease. His lecture will focus on organoids developed from bile duct cells and hepatocytes, and applications for disease modeling in cancer, hereditary disease and regenerative medicine strategies.Hans Clevers

This half-day program provides an overview of both current and emerging therapies for common liver diseases. Additionally, it will enhance knowledge around diagnostics and highlight the roles of collaborating professionals.Yuko Kono John E. Eaton Dr. John Eaton is a transplant Hepatologist with a clinical and research focus on cholestatic liver diseases with an emphasis on primary sclerosing cholangitis (PSC) and related comorbid conditions. His clinical practice involves seeing a large volume of patients with PSC and PSC complicated by cholangiocarcinoma. Dr.

The goal of this program is to highlight the hepatic manifestations of various diseases endemic or epidemic in the Tropics. These diseases include viral A and E hepatitis; hepatic manifestations of viral epidemics like Dengue, SARS, and Zika virus; bacterial infections like typhoid; and parasitic diseases like malaria.Kenneth Sherman Harshad Devarbhavi Maria Cassia Mendes Edna Strauss Robert Gish Robert G. Gish, MD AGAF, FAST, FAASLD is currently an Adjunct Professor of Medicine at the University of Nevada Schools of Medicine in Las Vegas and in Reno.

Yanling Ma, Olga V. Belyaeva, Philip M. Brown, Koji Fujita, Katherine Valles, Suman Karki, Ynto S. de Boer, Christopher Koh, Yanhua Chen, Xiaomeng Du, Samuel K. Handelman, Vincent Chen, Elizabeth K. Speliotes, Cara Nestlerode, Emmanuel Thomas, David E. Kleiner, Joseph M. Zmuda, Arun J. Sanyal, (for the Nonalcoholic Steatohepatitis Clinical Research Network), Natalia Y. Kedishvili, T. Jake Liang, Yaron Rotman – 11 November 2018 – Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease.

John A. Geha, Joseph D. Geha, Christine A. O’Mahony, Ronald T. Cotton, Thao N. Galvan, Abbas Rana, John A. Goss – 11 November 2018

Carla Serra, Alessandro Cucchetti, Cristina Felicani, Cristina Mosconi, Antonio De Cinque, Rita Golfieri, Pietro Andreone, Giorgio Ercolani, Lorenzo Maroni, Matteo Ravaioli, Antonia D’Errico, Antonio Daniele Pinna, Matteo Cescon – 11 November 2018 – Radiofrequency ablation (RFA) represents a potentially curative option for early‐stage hepatocellular carcinoma (HCC). This study aims at evaluating the histologic response after RFA of small HCCs arising in cirrhosis. Data were reviewed from 78 patients with de novo HCCs who were treated with RFA and subsequently transplanted.

This program will review the current status of liver transplantation in the setting of combined organ transplants (i.e., liver/intestine/multi-visceral, liver/ kidney, liver/heart and liver/lung transplantation). Indications, pathophysiology, operative management, post-transplant care and outcomes will be discussed in the context of specific extra-hepatic organ dysfunction and combined organ transplantation.

Sapana Verma, Subhash Gupta – 10 November 2018

Leticia Muñoz, María‐José Borrero, María Úbeda, Elisa Conde, Rosa del Campo, Macarena Rodríguez‐Serrano, Margaret Lario, Ana‐María Sánchez‐Díaz, Oscar Pastor, David Díaz, Laura García‐Bermejo, Jorge Monserrat, Melchor Álvarez‐Mon, Agustín Albillos – 10 November 2018 – In cirrhosis, intestinal dysbiosis, intestinal barrier impairment, and systemic immune system abnormalities lead to gut bacterial translocation (GBT) and bacterial infection. However, intestinal immune system dysfunction and its contribution to barrier damage are poorly understood.

This program discusses different, yet related, basic molecular mechanisms of hepatic damage and inflammation fundamental for the development of various types of liver diseases. Discussions will cover the mechanisms for vesicle formation and  endocytosis, how secretion of exosomes occurs upon inflammasome activation, the impact of immune cell-derived vesicles on fibrosis and the process of collagen secretion. The second part of the program focuses on novel signaling pathways  involved in disease resolution.